Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational? (Q39262493)

10 September 2017

Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational? (English)

1 reference

10 September 2017

metastatic breast cancer

1 reference

1 reference

Jian Zhang

1

1 reference

10 September 2017

Shi-Yang Gu

2

1 reference

10 September 2017

Yu Gan

3

1 reference

10 September 2017

Zhong-Hua Wang

4

1 reference

10 September 2017

Bi-Yun Wang

5

1 reference

10 September 2017

Hai-Yi Guo

6

1 reference

10 September 2017

Jia-Lei Wang

7

1 reference

10 September 2017

Lei-Ping Wang

8

1 reference

10 September 2017

Xin-Min Zhao

9

1 reference

10 September 2017

Xi-Chun Hu

10

1 reference

10 September 2017

2 October 2012

1 reference

Cancer Chemotherapy and Pharmacology

10 September 2017

1 reference

10 September 2017

71

1 reference

10 September 2017

1

1 reference

10 September 2017

103-113

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-012-1983-y

10 September 2017

0 references

cites work

Treatment of metastatic breast cancer: looking towards the future

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

First line chemotherapy of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Use of MTT colorimetric assay to measure cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Single agent versus combination chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Coo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1983-Y

10.1007/S00280-012-1983-Y

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference